S&P 500   3,306.71 (-1.50%)
DOW   27,565.36 (-1.21%)
QQQ   263.63 (-2.47%)
AAPL   106.60 (-3.39%)
MSFT   197.00 (-2.91%)
FB   250.94 (-1.52%)
GOOGL   1,436.10 (-3.43%)
AMZN   2,918.00 (-3.02%)
NVDA   480.59 (-3.60%)
TSLA   431.31 (+1.86%)
BABA   271.59 (-1.50%)
CGC   16.26 (-0.85%)
GE   6.90 (-2.13%)
MU   50.22 (-1.49%)
AMD   74.08 (-3.23%)
T   28.95 (-0.41%)
F   7.25 (-0.41%)
ACB   6.42 (-6.82%)
GILD   64.13 (-1.40%)
NFLX   460.99 (-1.96%)
DIS   128.57 (-1.27%)
BAC   25.30 (-0.20%)
BA   162.61 (-2.94%)
S&P 500   3,306.71 (-1.50%)
DOW   27,565.36 (-1.21%)
QQQ   263.63 (-2.47%)
AAPL   106.60 (-3.39%)
MSFT   197.00 (-2.91%)
FB   250.94 (-1.52%)
GOOGL   1,436.10 (-3.43%)
AMZN   2,918.00 (-3.02%)
NVDA   480.59 (-3.60%)
TSLA   431.31 (+1.86%)
BABA   271.59 (-1.50%)
CGC   16.26 (-0.85%)
GE   6.90 (-2.13%)
MU   50.22 (-1.49%)
AMD   74.08 (-3.23%)
T   28.95 (-0.41%)
F   7.25 (-0.41%)
ACB   6.42 (-6.82%)
GILD   64.13 (-1.40%)
NFLX   460.99 (-1.96%)
DIS   128.57 (-1.27%)
BAC   25.30 (-0.20%)
BA   162.61 (-2.94%)
S&P 500   3,306.71 (-1.50%)
DOW   27,565.36 (-1.21%)
QQQ   263.63 (-2.47%)
AAPL   106.60 (-3.39%)
MSFT   197.00 (-2.91%)
FB   250.94 (-1.52%)
GOOGL   1,436.10 (-3.43%)
AMZN   2,918.00 (-3.02%)
NVDA   480.59 (-3.60%)
TSLA   431.31 (+1.86%)
BABA   271.59 (-1.50%)
CGC   16.26 (-0.85%)
GE   6.90 (-2.13%)
MU   50.22 (-1.49%)
AMD   74.08 (-3.23%)
T   28.95 (-0.41%)
F   7.25 (-0.41%)
ACB   6.42 (-6.82%)
GILD   64.13 (-1.40%)
NFLX   460.99 (-1.96%)
DIS   128.57 (-1.27%)
BAC   25.30 (-0.20%)
BA   162.61 (-2.94%)
S&P 500   3,306.71 (-1.50%)
DOW   27,565.36 (-1.21%)
QQQ   263.63 (-2.47%)
AAPL   106.60 (-3.39%)
MSFT   197.00 (-2.91%)
FB   250.94 (-1.52%)
GOOGL   1,436.10 (-3.43%)
AMZN   2,918.00 (-3.02%)
NVDA   480.59 (-3.60%)
TSLA   431.31 (+1.86%)
BABA   271.59 (-1.50%)
CGC   16.26 (-0.85%)
GE   6.90 (-2.13%)
MU   50.22 (-1.49%)
AMD   74.08 (-3.23%)
T   28.95 (-0.41%)
F   7.25 (-0.41%)
ACB   6.42 (-6.82%)
GILD   64.13 (-1.40%)
NFLX   460.99 (-1.96%)
DIS   128.57 (-1.27%)
BAC   25.30 (-0.20%)
BA   162.61 (-2.94%)
Log in
NASDAQ:NDRA

ENDRA Life Sciences Stock Forecast, Price & News

$0.77
-0.01 (-1.28 %)
(As of 09/18/2020 12:29 PM ET)
Add
Compare
Today's Range
$0.76
Now: $0.77
$0.77
50-Day Range
$0.72
MA: $0.88
$1.04
52-Week Range
$0.60
Now: $0.77
$2.25
Volume2,400 shs
Average Volume296,684 shs
Market Capitalization$16.14 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58
ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NDRA
CUSIPN/A
Phone734-335-0468

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10,000.00
Book Value$0.57 per share

Profitability

Net Income$-13,310,000.00

Miscellaneous

Employees11
Market Cap$16.14 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$0.77
-0.01 (-1.28 %)
(As of 09/18/2020 12:29 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NDRA News and Ratings via Email

Sign-up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ENDRA Life Sciences (NASDAQ:NDRA) Frequently Asked Questions

How has ENDRA Life Sciences' stock been impacted by COVID-19 (Coronavirus)?

ENDRA Life Sciences' stock was trading at $1.0029 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NDRA shares have decreased by 23.5% and is now trading at $0.7670.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ENDRA Life Sciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ENDRA Life Sciences
.

When is ENDRA Life Sciences' next earnings date?

ENDRA Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for ENDRA Life Sciences
.

How were ENDRA Life Sciences' earnings last quarter?

ENDRA Life Sciences Inc (NASDAQ:NDRA) issued its quarterly earnings data on Friday, August, 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.07.
View ENDRA Life Sciences' earnings history
.

What price target have analysts set for NDRA?

1 brokerages have issued twelve-month price targets for ENDRA Life Sciences' shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate ENDRA Life Sciences' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 682.3% from the stock's current price.
View analysts' price targets for ENDRA Life Sciences
.

Who are some of ENDRA Life Sciences' key competitors?

What other stocks do shareholders of ENDRA Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ENDRA Life Sciences investors own include Advanced Micro Devices (AMD), Acasti Pharma (ACST), Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), Actinium Pharmaceuticals (ATNM), BioNano Genomics (BNGO), electroCore (ECOR), TherapeuticsMD (TXMD) and AbbVie (ABBV).

Who are ENDRA Life Sciences' key executives?

ENDRA Life Sciences' management team includes the following people:
  • Mr. Francois Michelon, Chairman & CEO (Age 53)
  • Mr. David R. Wells, CFO & Sec. (Age 57)
  • Mr. Michael Thornton, Chief Technology Officer (Age 51)
  • Dr. Jonathan Behr Ph.D., Co-Founder
  • Mr. Steve Freeman, HR Leader

When did ENDRA Life Sciences IPO?

(NDRA) raised $10 million in an initial public offering on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities served as the underwriters for the IPO.

What is ENDRA Life Sciences' stock symbol?

ENDRA Life Sciences trades on the NASDAQ under the ticker symbol "NDRA."

Who are ENDRA Life Sciences' major shareholders?

ENDRA Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include ICM Asset Management Inc. WA (2.45%), Gladstone Institutional Advisory LLC (0.22%) and Virtu Financial LLC (0.16%). Company insiders that own ENDRA Life Sciences stock include Anthony Digiandomenico, David R Wells, Longboard Capital Advisors, Ll, Lou Basenese, Michael Harsh and Michael Milos Thornton.
View institutional ownership trends for ENDRA Life Sciences
.

Which major investors are selling ENDRA Life Sciences stock?

NDRA stock was sold by a variety of institutional investors in the last quarter, including ICM Asset Management Inc. WA.
View insider buying and selling activity for ENDRA Life Sciences
.

Which major investors are buying ENDRA Life Sciences stock?

NDRA stock was bought by a variety of institutional investors in the last quarter, including Gladstone Institutional Advisory LLC, and Virtu Financial LLC. Company insiders that have bought ENDRA Life Sciences stock in the last two years include Anthony Digiandomenico, David R Wells, Lou Basenese, Michael Harsh, and Michael Milos Thornton.
View insider buying and selling activity for ENDRA Life Sciences
.

How do I buy shares of ENDRA Life Sciences?

Shares of NDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ENDRA Life Sciences' stock price today?

One share of NDRA stock can currently be purchased for approximately $0.77.

How big of a company is ENDRA Life Sciences?

ENDRA Life Sciences has a market capitalization of $16.08 million and generates $10,000.00 in revenue each year. The company earns $-13,310,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. ENDRA Life Sciences employs 11 workers across the globe.

What is ENDRA Life Sciences' official website?

The official website for ENDRA Life Sciences is www.endrainc.com.

How can I contact ENDRA Life Sciences?

ENDRA Life Sciences' mailing address is 3600 GREEN COURT SUITE 350, ANN ARBOR MI, 48105. The company can be reached via phone at 734-335-0468 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.